Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study
2009
Feliu, Jaime | Firvida, Jose Luis | Castro, Javier | Madroñal, Catherina | Rodríguez-Jaráiz, Angeles | Salgado, Mercedes | Belda-Iniesta, Cristóbal | Casado, Enrique | García-Mata, Jesús | González Barón, Manuel
Purpose To determine the efficacy and safety of the combination therapy with docetaxel and cisplatin (CDDP) at low doses in elderly patients with advanced NSCLC. Patients and methods A total of 42 patients aged >=70 years with previously untreated advanced NSCLC received docetaxel 75 mg/m² plus CDDP 50 mg/m² on day 1. The regimen was repeated every 21 days. Patients received a minimum of three courses unless progressive disease was detected. Results By intent-to-treat analysis, the overall response rate was 31% (95% CI, 17.8-47.2%). A total of 18 patients (43%) had stable disease and 11 (26%) progressed. Median time to progression was 5.2 months. Overall median survival was 8.9 months, with 1-year actuarial survival rate of 41%. Eastern Cooperative Oncology Group performance status was improved in 18 patients (43%). The chemotherapy regimen was well tolerated. A total of 11 patients (26%) had grade 3/4 adverse events: 7 (17%) neutropenia (one of them was diagnosed with febrile neutropenia), 3 (7%) asthenia, 3 (7%) nausea/vomiting, 1 (2%) diarrhea, 1 (2%) thrombocytopenia and 1 (2%) neurotoxicity. No death due to toxicity was seen. Conclusion The combination of low-dose CDDP and docetaxel for elderly patients with advanced NSCLC is an efficient and well-tolerated chemotherapeutic approach.
Показать больше [+] Меньше [-]Ключевые слова АГРОВОК
Библиографическая информация
Эту запись предоставил National Agricultural Library